Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | BCR | P11274 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434225 | 0.94 | ABL1 (0.54) | ABL1BCRAURKAACKR3 | |
| SCHEMBL1434063 | 0.93 | ABL1 (0.63) | ABL1BCRCYP2C9PTGER1AURKA | |
| SCHEMBL1434116 | 0.92 | ABL1 (0.50) | ABL1BCRCYP2C9PTGER1ACKR3 | |
| SCHEMBL1433921 | 0.92 | ABL1 (0.62) | ABL1BCRCYP2C9PTGER1AURKA | |
| SCHEMBL1433967 | 0.92 | ABL1 (0.62) | ABL1BCRCYP2C9PTGER1AURKA | |
| SCHEMBL1434082 | 0.92 | ABL1 (0.62) | ABL1BCRCYP2C9PTGER1AURKA | |
| SCHEMBL1434591 | 0.91 | ABL1 (0.65) | ABL1BCRCYP2C9PTGER1AURKA | |
| SCHEMBL1433799 | 0.91 | ABL1 (0.61) | ABL1BCRCYP2C9PTGER1AURKA | |
| SCHEMBL1434583 | 0.91 | ABL1 (0.61) | ABL1BCRCYP2C9PTGER1AURKA | |
| SCHEMBL1433562 | 0.91 | ABL1 (0.61) | ABL1BCRCYP2C9PTGER1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | claimed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | claimed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | claimed |
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | disclosed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | disclosed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | ABL1 556/4885BCR 600/4885CYP2C9 326/4885 |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | ABL1 556/4885BCR 600/4885CYP2C9 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.